Core Viewpoint - Boston Scientific is acquiring the remaining equity in Nalu Medical for approximately $533 million in cash, enhancing its chronic pain treatment portfolio [1][2] Group 1: Acquisition Details - The acquisition provides Boston Scientific access to Nalu's neurostimulation device, which utilizes peripheral nerve stimulation (PNS) for targeted pain relief [1][3] - This year, Boston Scientific has made several acquisitions, including a $443 million payment for Bolt Medical [2] - The deal is expected to be immaterial to Boston Scientific's adjusted profit in 2026 but slightly accretive in 2027, with increasing benefits thereafter [5] Group 2: Product and Market Insights - Nalu's therapy employs mild electrical impulses to disrupt pain signals before they reach the brain and features a miniaturized, battery-free implant powered wirelessly [3] - The device received FDA clearance for PNS in 2019 and for spinal cord stimulation (SCS) in 2020 [4] - Analysts note that Nalu's PNS system is more robust compared to competitors, indicating potential market share gains, while expectations for SCS are more conservative due to Boston's existing offerings [4] Group 3: Market Reaction - Following the announcement, shares of Boston Scientific rose approximately 1% in early trading [5]